January 2010 Meeting Announcement, Delaware Valley Mass Spectrometry Discussion Group
- Topic: "Quantification of Disease Biomarkers Using Liquid Chromatography-Mass Spectrometry
- Speaker: Ian A. Blair, University of Pennsylvania
- Date: Monday, January 11, 2010. 6:30 PM
- Time: Social Hour: 6:30 PM.
Talk: 7:30 PM.
Please RSVP to Bill Simonsick firstname.lastname@example.org by Thursday January 7th.
- Place: Department of Chemistry, Villanova University (Room 102, Mendel Hall)
The meaning of the term biomarker has been standardized by the National Institutes of Health as "a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention". The ability of a biomarker to enhance the diagnosis of disease and quality and efficacy of clinical care depends upon the sensitivity and specificity of the bioanalytical procedure as well as the sensitivity and specificity in detecting or monitoring the disease of interest. Stable isotope dilution methodology in combination with liquid chromatography-tandem mass spectrometry (LC-MS/MS) provides the highest analytical specificity possible for quantitative determinations. This methodology is now widely used in the discovery and validation of putative exposure and disease biomarkers. Our laboratory has used stable isotope dilution LC-MS/MS for the analysis of small molecule exposure biomarkers, small molecule disease biomarkers (steroids, folates, lipids, DNA-adducts, glutathione-adducts) as well as peptide and protein disease biomarkers. Requirements for the use of smaller and smaller amounts of precious biological samples have stimulated ever increasing needs to improve the sensitivity of routine biomarker analyses. The use of pre-ionized (quaternary) derivatives is proving to be very successful for providing substantial increases in LC-MS sensitivity for the analysis of many different biomarkers. Some recent examples of this approach for the quantification of disease biomarkers will be discussed.
Born in the UK, Ian earned his BSc in Chemistry at Imperial College, London where he conducted his final year research project in 1968 under the direction of Derek Barton. He joined the Barton laboratory at Imperial College in the fall of 1968 to begin his PhD research in Organic Chemistry. The following year Derek Barton received the Nobel Prize in Chemistry for his seminal contributions to the field of conformational analysis. Ian completed his PhD in Organic Chemistry in 1971 and then took a position funded by the British Council at Makerere University in Uganda. This was followed by research positions in Australia where he developed his lifetime interest in mass spectrometry through working at Adelaide University with John Bowie on ion cyclotron resonance mass spectrometry and with George Phillipou on gas chromatography-mass spectrometry. He returned to the UK in 1979 to take up a faculty position at the Hammersmith Hospital, which is now part of Imperial College, London. This position in the Department of Clinical Pharmacology was vacated when Tom Baillie left to work with Al Burlingame at UCSF. In 1983, Ian was recruited to Vanderbilt University as a Professor of Pharmacology in order to develop and run a Mass Spectrometry Center. He was subsequently named to the endowed Derek Barton Chair of Pharmacology. In 1997, Ian moved to his current positions at the University of Pennsylvania where he is the AN Richards Professor of Pharmacology and Director of the Center for Cancer Pharmacology. In 2001 he also became Director of the Proteomics and Systems Biology Facility at the University of Pennsylvania. Ian has published over 260-refereed manuscripts most of which have involved the use of mass spectrometry. In 2000, he discovered a new mass spectrometry technique known as electron capture atmospheric pressure chemical ionization. His 2003 paper describing the application of this technique to chiral lipid analysis was awarded the RCM Beynon Prize. In 2005, Ian was elected as a Fellow of the American Association for the Advancement of Science. In 2006, he was given the Dean's award for graduate student training at the University of Pennsylvania and was elected as a Fellow of the American Association of Pharmaceutical Scientists. Ian is on the editorial boards of the Journal of Biological Chemistry, Chemical Research in Toxicology, Journal of Mass Spectrometry, and Current Drug Metabolism, and he regularly serves on NIH study sections. Most recently he became a member of the Drug Discovery and Molecular Pharmacology (DMP) Study Section.
Please send any comments, corrections, or suggestions to
This page has been accessed
times since 9/15 /96 .
Last Updated 9/16/2009